Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

t assume any responsibility for updating any forward-looking statements. VIROHARMA INCORPORATEDSelected Financial Information(unaudited)Consolidated Statements of Operations:Three months endedYear ended(in thousands, except per share data)

December 31,December 31,2012201120122011Revenues:Net product sales

$
,490$
45,575$
427,933$
544,374Costs and Expenses:Cost of sales (excluding amortization

 of product rights)

26,82719,683108,54779,976Research and development

19,14212,70767,70966,477Selling, general and administrative

50,97836,022174,315127,775Intangible amortization

8,8577,77435,30131,035Impairment loss

---8,495Other operating expenses

2,710948,7188,488Total costs and expenses

108,51476,280394,590322,246Operating income (loss) 

(2,024)69,29533,343222,128Interest income

188140594655Interest expense

(3,599)(3,475)(14,093)(12,640)Other income (loss), net

3,941(2,563)(823)(2,136)Income (loss) before income tax expense

(1,494)63,39719,021208,007Income tax expense 

2,48910,21913,41067,348Net income (loss) 

$
(3,983)$
53,178$
5,611$
40,659Basic net income (loss) per share

$
(0.06)$
.75$
.08$
.89Diluted net income (loss) per share

$
(0.06)$
.65$
.08$
.68Shares used in computing net income  per share:Basic

65,38570,49968,21474,517Diluted

65,38584,49371,76488,076VIROPHARMA INCORPORATEDSelected Financial Information(unaudited)Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted Net IncomeAn itemized reconciliation between net income (loss) and adjusted net income on a non-GAAP basis is as follows:(in thousands)

Three months endedTwelve months endedDecember 31,December 31,2012201120122011GAAP net  income (loss)

$
(3,983)$
53,178$
5,611$
40,659Adjustments:Non-cash interest expe
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/19/2014)... leading Dartmouth researcher, working with The Melanoma Genetics Consortium, ... today in the Journal of the National Cancer ... of melanoma. , "For the first time, we have ... telomeres play a part in the risk of developing ... PhD, School of Medicine at the University of Leeds ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 According to ... of the embattled blood-thinner Xarelto, named as defendants in ... Common Pleas, have moved the court to dismiss those ... not have sufficient connection with Philadelphia.* The cases include, ... al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which ...
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Pregnant women who live in leafy, ... birth weight babies, a new study suggests. Researchers analyzed ... found that expectant mothers who lived in a neighborhood with ... percent lower risk of very preterm birth (before 30 weeks) ... (30 to 36 weeks). Babies born to mothers who ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... a former psychiatric patient has been jailed for life for ... year in a Glasgow's Pollok Park. , ,He attacked ... from a psychiatric hospital where a judge had ordered he ... Robertson, a father of three from Glasgow, befriended James Smith ...
... consuming over eight cups of coffee a day risk spontaneous ... death was twice as likely among heavy coffee drinkers relative ... ,Adjusting for other risk factors weakened the association somewhat, ... of fetal death, Dr. Bodil Hammer Bech of the University ...
... findings that are being presented during the American Society ... Philadelphia, Pennsylvania, say that women are not being adequately ... Through analyses of the recently conducted renal trials showed ... may be the reason why the US Food and ...
... answer for may help cancer, researchers say.,A complex ... growth of tumours in tests in mice, reports online ... used by researchers in Gordon Jayson Manchester’s Christie’s Hospital ... During the tests, the sugar molecules were divided and ...
... have found a new model that shows how tumor ... the presence of microenvironment of tumor cells. // The ... cell to malignant cell is understood with the help ... new insights into the influence of the tumor cell ...
... training of new doctors in Britain. According to the Department of ... lack of cadavers and experts said more would be hit if ... ,The government has blamed rising medical student numbers, TV shows and ... years, the number of bodies being donated has fallen from 670 ...
Cached Medicine News:Health News:Man Bludgeons Friend, Gets Life Term 2Health News:Coffee In Pregnancy May Be Risky: Study 2Health News:New Model for understanding Tumor Metastasis 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: